Floatz logo

Natalizumab

Sarcoma

Institut du Cancer de Montpellier - Val d'AurelleN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

91 Active assets in the Sarcoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
Ifosfamide
City of Hope Medical Center
Phase 3BB
Cyclophosphamide
Essen Biotech
Phase 2BB
Carboplatin
OHSU Knight Cancer Institute
Phase 2BB
Inno-206
City of Hope Medical Center
Phase 3BB

View all 50 →

Same molecule, other indications

Natalizumab is also rated in:

relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
79 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
70 / 100
View asset →
secondary progressive multiple sclerosisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →